ellura™, the Only Cranberry Product on the Market Containing the Clinically Proven Effective Dosage of 36mg PACs, Assesses the Cochrane Review
Study illustrates the need of cranberry dosing standardization for efficacy
Atlanta, GA (PRWEB) October 24, 2012
ellura (http://www.myellura.com), the only dietary supplement on the market that is clinically proven to have the required dose of cranberry juice PAC to promote a clean urinary tract, issues today a response to the 2012 Cochrane Review.
“The ellura team applauds the Cochrane Review of cranberries for preventing urinary tract infections, which we believe fairly represents the connection between various cranberry products and urinary tract health,” says Terri Jackson Wade, CEO of Trōphikōs, the company that markets ellura in the U.S. “The key message from the Cochrane Review is that, while there is clinical proof that cranberries contain the anti-adhesion ingredient called PACs which can prevent UTIs, most cranberry products, including juices, do not contain enough of the PACs to be effective. The exception is cranberry tablets and capsules that contain the clinically proven 36mg PACs, and that are standardized by the validated measurement BL-DMAC. This is the rationale behind our product ellura.”
ellura is a natural cranberry supplement that helps to avoid the cycle of suffering and chronic antibiotic use associated with recurring UTIs by maintaining a clean urinary tract. ellura is the only product that contains the clinically proven 36mg PAC (proanthocyanidins) in one daily capsule to flush bacteria from the urinary tract and is the only cranberry supplement available in the U.S. that meets the standards of the French FDA (ANSES) health claim, the only issued nutritional health claim for cranberry worldwide.
ellura's executive team reports some points for clarification found in the Cochrane findings:
- In the majority of clinical studies that used “tablets and capsules”, the “cranberry powders” were insufficiently or wrongly characterized because the standard BL-DMAC method was not used. The PAC content they reported, reproduced by Cochrane as an example of compliance, was incorrect. One study reports the measurement of only the “A-type” PACs in the “powder” which is at present scientifically impossible to measure.
“The ellura team is passionate about the promise of prevention for millions of Americans who suffer from UTIs,” says Jackson Wade. “We plan to continue the march with additional clinical studies that show how ellura, with its 36mg PAC, is changing lives around the globe.”
# # #
For the original version on PRWeb visit: http://www.prweb.com/releases/prwebcranberry_supplement/urinary_tract_health/prweb10049643.htmView Comments and Join the Discussion!